BioSig Technologies (NSDQ:BSGM) announced today that it successfully completed 100 patient cases with its Pure EP electrocardiographic system.
The Pure EP is designed to acquire, digitize, measure, display and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures.
Westport, Conn.–based BioSig initiated its first clinical trial in November 2019 and is currently enrolling at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center (Austin, Texas) and Mayo Clinic’s Florida campus. The company conducted other cases at the Indiana University School of Medicine, Greenville Memorial Hospital and Santa Barbara Cottage Hospital.
BioSig completed procedures with the Pure EP system for people with persistent atrial fibrillation, ischemic ventricular tachycardias, PVC, atypical flutters and other forms of arrhythmias. In its latest letter to shareholders, the company said it plans to install Pure Ep at up to nine new centers before May 2020.
“We are responding to the requests in a methodical fashion in order to assess and meet the needs of these centers,” BioSig chairman & CEO Kenneth Londoner said in a news release. “We are running ahead of our plans stated in our November 2019 shareholder letter, based on the number of centers we are currently engaging to discuss potential new installations.”
